Tests BMS-986453 cell therapy in adults with relapsed or hard-to-treat multiple myeloma
Tests BMS-986453, a modified immune cell treatment, in adults with returning or resistant myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Key facts
- Where
- Birmingham, Boston, Denver, Duarte, Nashville, New Haven, New York, San Francisco, Seattle, Stanford, and Tampa, United StatesSee the 13 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding to treatment. It tests BMS-986453, a CAR T-cell therapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma that has come back and/or did not respond to treatment, with confirmed progression on or within 12 months of the last dose of the last anti-myeloma treatment.
- Earlier treatment
- In Part A and Part B Cohorts 1 and 2: earlier anti-myeloma treatment, including a proteasome inhibitor and an immunomodulatory agent.
Main reasons for not taking part
- Known active or past involvement of the central nervous system (CNS) by multiple myeloma
- Active or past plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or clinically significant amyloidosis
- Significant CNS disease such as seizure disorder, stroke, dementia, Parkinson's disease or cerebellar disease
- Clinically active psychosis
Read by machine on 9 November 2026.
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Colorado Blood Cancer InstituteDenver, United StatesTaking people
- City of Hope Comprehensive Cancer CenterDuarte, United StatesTaking people
- NashvilleNashville, United StatesNot yet recruiting
- Tennessee OncologyNashville, United StatesTaking people
- Yale Cancer CenterNew Haven, United StatesTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- UCSF Helen Diller Medical Center at Parnassus HeightsSan Francisco, United StatesTaking people
- Swedish Medical CenterSeattle, United StatesTaking people
- Stanford University Medical CenterStanford, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Trial code
- NCT06153251EU 2023-506003-26-00
- Record updated
- 18 March 2026
- Original description
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).Read full original descriptionShow less
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Inclusion: Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease; Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry; Participants in Part A and Part B Cohort 1 and in Part B Cohort 2 must have relapsed/refractory multiple myeloma and received previous antimyeloma therapy, including a proteasome inhibitor and an immunomodulatory agent; Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Participants must have adequate organ function.
Exclusion: Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma; Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis; Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis; Other protocol-defined inclusion/exclusion criteria apply.